Daiichi Sankyo and Merck voluntarily withdrew their B7-H3-directed ADC ifinatamab deruxtecan (i-dxd) BLA in extensive-stage small-cell lung cancer after disease progression on or after platinum chemotherapy. The withdrawal removes the regulatory application from the near-term review pipeline and signals continued difficulty translating clinical activity into an approvable profile. Separate reporting indicates the setback also included implications for earlier hopes around accelerated pathways, with regulators citing that the available data did not support an accelerated clearance request. While the BLA withdrawal doesn’t end development, it pauses formal FDA review and forces a reassessment of trial strategy. For companies competing in the ADC space, the news reinforces how target selection, patient stratification and endpoint design remain decisive for review outcomes. In the broader portfolio, Merck and Daiichi’s B7-H3 effort will now likely pivot toward new studies that can better address regulatory evidentiary thresholds.